Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Európska únia - slovenčina - EMA (European Medicines Agency)

medimmune llc - reassortant vírus chrípky (živej oslabenej) z týchto kmeňov:/california/7/2009 (h1n1)pdm09, ako kmeň, a/victoria/361/2011 (h3n2) ako kmeň, b/massachusetts/2/2012 ako kmeň - influenza, human; immunization - vakcíny - profylaxia chrípky u jedincov od 24 mesiacov do 18 rokov. použitie fluenz by sa malo zakladať na oficiálnych odporúčaniach.

Európska únia - slovenčina - EMA (European Medicines Agency)

alexion europe sas - sebelipáza alfa - lipidový metabolizmus, vrodené chyby - iné alimentárny trakt a metabolizmus výrobky, - kanuma je indikovaný na dlhodobú enzýmovú substitučnú liečbu (ert) u pacientov všetkých vekových skupín s nedostatkom lysozomálnej kyseliny lipázy (lal).

Európska únia - slovenčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Európska únia - slovenčina - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinúria, paroxysmálna - imunosupresíva - soliris je indikovaný u dospelých a detí na liečbu:paroxyzmálna nočné haemoglobinuria (pnh). dôkazy z klinických výhodou je preukázaná u pacientov s haemolysis s klinický príznak(s) svedčí o vysokej aktivity ochorenia, bez ohľadu na transfúziu históriu (pozri časť 5. atypické haemolytic-uremickým syndrómom (zariadenia). soliris je indikovaný u dospelých na liečbu:Žiaruvzdorné generalizované myasthenia gravis (gmg) u pacientov, ktorí sú anti-acetylcholínové receptory (achr) protilátky-pozitívne (pozri časť 5. neuromyelitis optica spektrum poruchy (nmosd) u pacientov, ktorí sú anti-aquaporin-4 (aqp4) protilátky-pozitívne s relapsujúcou priebeh ochorenia.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - rôzne kombinácie - 12 - antianaemica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

recordati industria chimica e farmaceutica s.p.a., taliansko - metoprolol - 58 - hypotensiva